IncobotulinumtoxinA

DRUG17 trials

Sponsors

Merz Pharmaceuticals GmbH, The Maas Clinic, DeNova Research, Yale University, Thomas Jefferson University

Conditions

Cerebral Palsy, SpasticElastosis SenilisEssential Tremor of the Upper LimbsGlabellar Frown LinesGlabellar Frown Lines and Canthal Lines and/or Horizontal Forehead Lines in the Upper FaceHabitual SnoringModerate to Severe Chronic Peripheral Neuropathic Pain (PNP) Due to Postherpetic Neuralgia (PHN) or Peripheral Nerve InjuryN/A, as no Specific Medical Condition Will be Treated

Early Phase 1

Xeomin Treatment of Glabellar Lines Using OLD Versus COLD

Clinical Testing of Beverly HillsGlabellar Frown Lines

Start: 2022-05-01End: 2023-02-28Target: 40Updated: 2022-03-31

Phase 1

A Study to Evaluate the Distribution of Botulinum Neurotoxin Type A Administered as Intradermal Injections, Comparing Different Doses, Concentrations, and Delivery Methods

CompletedNCT05585398

Merz Pharmaceuticals GmbHN/A, as no Specific Medical Condition Will be Treated

Start: 2022-10-19End: 2023-04-13Updated: 2023-06-22

Effects of Microtox on Facial Skin Quality, Fine Wrinkles, and Texture

CompletedNCT06604832

Kalpna Kay Durairaj, MD, FACSSkin Aging, Skin Wrinkling

Start: 2024-09-03End: 2025-09-16Updated: 2025-10-21

Phase 2

Dose Finding Study for a Botulinum Toxin Type A Injection to Treat Habitual Snoring

TerminatedNCT01515371

Merz Pharmaceuticals GmbHHabitual Snoring

Start: 2012-01-31End: 2012-11-30Updated: 2013-06-19

A Double-Blinded, Randomized Placebo Controlled Pilot Study Comparing the Efficacy and Safety of IncobotulinumtoxinA Versus Saline Injections to the Cheek Region in Patients With Rosacea

CompletedNCT01614743

DeNova ResearchRosacea

Start: 2012-06-30End: 2013-11-30Updated: 2020-10-08

IncobotulinumtoxinA for Treatment of Focal Cancer Pain After Surgery and/or Radiation

TerminatedNCT01931865

Yale UniversityPain

Start: 2012-09-30End: 2015-07-31Updated: 2015-12-31

Investigation of Efficacy of incobotulinumtoxinA (Xeomin) in Relieving Symptoms of Restless Leg Syndrome.

CompletedNCT01931878

Yale UniversityRestless Leg Syndrome

Start: 2012-09-30End: 2015-08-31Updated: 2016-03-21

Incobotulinum Toxin for the Treatment of Trigeminal Neuralgia

TerminatedNCT02088632

Thomas Jefferson UniversityTrigeminal Neuralgia

Start: 2014-03-14End: 2016-10-19Updated: 2023-06-28

Botulinum Toxin A to Treat Arm Tremor

CompletedNCT02207946

Merz Pharmaceuticals GmbHEssential Tremor of the Upper Limbs

Start: 2014-12-05End: 2016-09-26Updated: 2021-02-18

Investigation of the Efficacy and Safety of IncobotulinumtoxinA (Xeomin) in Parkinson's Tremor: A Customized Approach

CompletedNCT02419313

Yale UniversityParkinson, Tremor

Start: 2012-08-31End: 2015-09-30Updated: 2016-03-14

A Clinical Trial to Investigate Efficacy and Safety of NT 201 Injections Compared With Placebo Injections in Participants Aged 18 Years and Older With Chronic Nerve Pain After Shingles or Nerve Injury

CompletedNCT06091020

Merz Therapeutics GmbHModerate to Severe Chronic Peripheral Neuropathic Pain (PNP) Due to Postherpetic Neuralgia (PHN) or Peripheral Nerve Injury

Start: 2023-11-22End: 2025-07-04Updated: 2025-07-24

Phase 3

Efficacy and Safety Dose Titration Study of Botulinum Toxin Type A to Treat Spasticity in the Leg and Arm

CompletedNCT01603459

Merz Pharmaceuticals GmbHSpasticity of the Upper and Lower Limb Due to Cerebral Causes

Start: 2012-05-31End: 2014-09-30Updated: 2017-04-26

Phase 4

Comparison of Escalating Doses of IncobotulinumtoxinA (Xeomin®) in the Treatment of Glabellar Rhytids

The Maas ClinicElastosis Senilis, Skin Aging

Start: 2014-09-30End: 2015-12-31Target: 15Updated: 2014-09-30

The Treatment of Glabellar Frown Lines

CompletedNCT02096081

Merz North America, Inc.Glabellar Frown Lines

Start: 2014-02-28End: 2014-11-30Updated: 2017-10-19

Effects of Botulinum Neurotoxin Type A (BoNT/A) Free of Complexing Proteins in the Spastic Equinovarus Foot

CompletedNCT03044080

Parc de Salut MarStroke Rehabilitation, Stroke Rehabilitation Spasticity Management

Start: 2015-01-01End: 2017-09-30Updated: 2017-10-20

Unknown Phase

Effect of Video Game-assisted and BoNT-A Injection Therapy on Spasticity, Activity and Participation in CP Patients

Sunnaas Rehabilitation HospitalCerebral Palsy, Spastic

Start: 2020-02-17End: 2022-03-01Target: 25Updated: 2020-02-28

Longitudinal Evaluation and Real-world Evidence of NT201

TerminatedNCT05222607

Merz North America, Inc.Glabellar Frown Lines and Canthal Lines and/or Horizontal Forehead Lines in the Upper Face

Start: 2023-02-10End: 2023-05-18Updated: 2023-06-07

Related Papers

Tolerability and Efficacy of Customized IncobotulinumtoxinA Injections for Essential Tremor: A Randomized, Double-Blind, Placebo-Controlled Study

Toxins2020-12-2026 citations

Goal analysis in patients with limb spasticity treated with incobotulinumtoxinA in the TOWER study

Disability and Rehabilitation2020-08-175 citations

Efficacy of incobotulinumtoxinA for the treatment of adult lower-limb post-stroke spasticity, including pes equinovarus.

2020-04-1211 citations

Quality of life in subjects with upper- and lower-limb spasticity treated with incobotulinumtoxinA

Health and Quality of Life Outcomes2020-03-0412 citations

Post hoc analysis of the improvement in shoulder spasticity and safety observed following treatment with incobotulinumtoxinA.

2020-03-018 citations

Botulinum Toxin in Parkinson Disease Tremor: A Randomized, Double-Blind, Placebo-Controlled Study With a Customized Injection Approach.

2017-08-0545 citations

Safety and efficacy of incobotulinumtoxinA doses up to 800 U in limb spasticity: The TOWER study.

2017-03-1077 citations

Escalating Doses of IncobotulinumtoxinA (400U-800U) Lead to Increasing Improvements in Disability Due to Multifocal Upper- and Lower-Limb Spasticity (P3.295)

Neurology2016-04-05

TOWER: Design of an Open‐Label Incobotulinumtoxina Dose‐Titration Study (≤800 U) In Lower‐ and Upper‐Limb Spasticity

PM&R2013-09-01